Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region

Chiao‐Ling Li, Chen‐Yu Li, You‐Yu Lin, Ming‐Chih Ho, Ding‐Shinn Chen, Pei‐Jer Chen, Shiou‐Hwei Yeh – 2 August 2018 – The gender disparity of hepatocellular carcinoma (HCC) is most striking in hepatitis B virus (HBV)‐related cases. The majority of such HCC cases contain integrated HBV, and some hotspot integrations, such as those in the telomerase reverse transcriptase gene (TERT) promoter, activate gene expression to drive carcinogenesis.

Global DNA 5‐Hydroxymethylcytosine and 5‐Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma

Jiao Liu, Jinhua Jiang, Jiezhen Mo, Dan Liu, Dan Cao, Hailin Wang, Yufei He, Hongyang Wang – 2 August 2018 – Methylation of the fifth position of cytosine (5mC) is an important epigenetic modification of DNA. It has been shown that the oxidized derivatives of 5mC, namely 5‐hydroxymethylcytosine (5hmC), 5‐formylcytosine (5fC), and 5‐carboxylcytosine (5caC), are in dynamic existence and have distinct regulatory functions.

Impact of the Treating Hospital on Care Outcomes for Hepatocellular Carcinoma

Ronald T. Cotton, Hop S. Tran Cao, Abbas A. Rana, Yvonne H. Sada, David A. Axelrod, John A. Goss, Mark A. Wilson, Steven A. Curley, Nader N. Massarweh – 2 August 2018 – Multidisciplinary hepatocellular carcinoma (HCC) treatment is associated with optimal outcomes. There are few data analyzing the impact of treating hospitals' therapeutic offerings on survival. We performed a retrospective cohort study of patients aged 18‐70 years with HCC in the National Cancer Database (2004‐2012).

Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis

Edward J. Gane, Catherine A. Stedman, Christian Schwabe, Leen Vijgen, Sushmita Chanda, Thomas N. Kakuda, John Fry, Lawrence M. Blatt, Matthew W. McClure – 2 August 2018 – This open‐label, phase IIa study assessed the safety, pharmacokinetics, and efficacy of direct‐acting antiviral agent (DAA) regimens in patients with chronic hepatitis C virus (HCV) infection. Multiple 6‐12‐week oral regimens of 400‐800 mg once daily (QD) AL‐335 + 50 mg QD/every other day odalasvir ± 75‐150 mg QD simeprevir were evaluated in treatment‐naïve, HCV genotype (GT)1/3‐infected patients without cirrhosis.

Liver Transplant Listing in Pediatric Acute Liver Failure: Practices and Participant Characteristics

James E. Squires, David A. Rudnick, Regina M. Hardison, Simon Horslen, Vicky L. Ng, Estella M. Alonso, Steven H. Belle, Robert H. Squires – 2 August 2018 – Liver transplant (LT) decisions in pediatric acute liver failure (PALF) are complex. Three phases of the PALF registry, containing data on 1,144 participants over 15 years, were interrogated to characterize clinical features associated with listing status. A decrease in the cumulative incidence of listing (P < 0.005) and receiving (P < 0.05) LT occurred without an increase in the cumulative incidence of death (P = 0.67).

Lactate Improves Prediction of Short‐Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study

Andreas Drolz, Thomas Horvatits, Karoline Rutter, Felix Landahl, Kevin Roedl, Philippe Meersseman, Alexander Wilmer, Johannes Kluwe, Ansgar W. Lohse, Stefan Kluge, Michael Trauner, Valentin Fuhrmann – 2 August 2018 – Lactate levels and lactate clearance are known predictors of outcome in critically ill patients in the intensive care unit (ICU). The prognostic value of lactate is not well established in liver cirrhosis and acute‐on‐chronic liver failure (ACLF). The aim of this study was to assess the prognostic value of lactate levels and clearance in critically ill patients with cirrhosis.

Reply

Norah A. Terrault, Robert S. Brown, Anna SF Lok, John B Wong, Natalie H Bzowej, Kyong‐Mi Chang, Jessica P Hwang, Maureen M Jonas, Brian J McMahon – 2 August 2018

Subscribe to